Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. 2009

Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Jordana, Zabrze, Poland. eszliszka@sum.edu.pl

Chalcones exhibit chemopreventive and antitumor effects. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a naturally occurring anticancer agent that induces apoptosis in cancer cells and is not toxic to normal cells. We examined the cytotoxic and apoptotic effect of five chalcones in combination with TRAIL on prostate cancer cells. The cytotoxicity was evaluated by the MTT and LDH assays. The apoptosis was determined using flow cytometry with annexin V-FITC. Our study showed that all five tested chalcones: chalcone, licochalcone-A, isobavachalcone, xanthohumol, butein markedly augmented TRAIL-mediated apoptosis and cytotoxicity in prostate cancer cells and confirmed the significant role of chalcones in chemoprevention of prostate cancer.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016588 Anticarcinogenic Agents Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. Anti-Carcinogenic Agents,Anti-Carcinogenic Drugs,Anti-Carcinogenic Effect,Anti-Carcinogenic Effects,Anticarcinogenic Drugs,Anticarcinogenic Effect,Anticarcinogenic Effects,Anticarcinogens,Agents, Anti-Carcinogenic,Agents, Anticarcinogenic,Anti Carcinogenic Agents,Anti Carcinogenic Drugs,Anti Carcinogenic Effect,Anti Carcinogenic Effects,Drugs, Anti-Carcinogenic,Drugs, Anticarcinogenic,Effect, Anti-Carcinogenic,Effect, Anticarcinogenic,Effects, Anti-Carcinogenic,Effects, Anticarcinogenic
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047188 Chalcones Derivatives of CHALCONE that are important intermediates in the formation of FLAVONOIDS with anti-fungal, anti-bacterial, anti-inflammatory, and anti-tumor properties. 1,3-Diphenyl-propanediones,1,3-Diphenyl-propenones,1,3-Diphenylpropanediones,1,3-Diphenylpropenones,Chalconoids,1,3 Diphenyl propanediones,1,3 Diphenyl propenones,1,3 Diphenylpropanediones,1,3 Diphenylpropenones
D053221 TNF-Related Apoptosis-Inducing Ligand A transmembrane-protein belonging to the TNF family of intercellular signaling proteins. It is a widely expressed ligand that activates APOPTOSIS by binding to TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTORS. The membrane-bound form of the protein can be cleaved by specific CYSTEINE ENDOPEPTIDASES to form a soluble ligand form. Tumor Necrosis Factor Ligand Superfamily Member 10,Apo-2 Ligand,Apo-2L Protein,CD253 Antigen,TNF Superfamily, Member 10,TRAIL Protein,Antigen, CD253,Apo 2 Ligand,Apo 2L Protein,Apoptosis-Inducing Ligand, TNF-Related,TNF Related Apoptosis Inducing Ligand

Related Publications

Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
July 2002, Cancer chemotherapy and pharmacology,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
July 2004, Cancer letters,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
January 2018, Asian journal of andrology,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
May 2002, International journal of oncology,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
October 2022, Toxicology in vitro : an international journal published in association with BIBRA,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
January 2015, Anti-cancer drugs,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
October 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
October 2007, Cancer research,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
January 2005, Journal of experimental therapeutics & oncology,
Ewelina Szliszka, and Zenon P Czuba, and Bogdan Mazur, and Lukasz Sedek, and Andrzej Paradysz, and Wojciech Krol
April 2011, International journal of oncology,
Copied contents to your clipboard!